GNNSF (Genscript Biotech) Total Receivables: $145.1 Mil (As of Dec. 2025)


GNNSF Genscript Biotech Corp GNNSF
66 GF Score
Price $1.60
GF Value $2.50
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Genscript Biotech Total Receivables?

Genscript Biotech GNNSF 66 Total Receivables is $145.1 Mil as of Dec. 2025. GuruFocus rates GNNSF with a GF Score™ of 66/100 and a GF Value™ of $2.50 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Genscript Biotech's Total Receivables for the quarter that ended in Dec. 2025 was $145.1 Mil.

Genscript Biotech Total Receivables Related Terms

Genscript Biotech Total Receivables Historical Data

* Premium members only.

The historical data trend for Genscript Biotech's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genscript Biotech Total Receivables Chart

Genscript Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 147.56 149.99 273.66 118.72 145.07

Genscript Biotech Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 273.66 218.13 118.72 156.67 145.07
GNNSF
66GF Score
Genscript Biotech Corp GNNSF
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genscript Biotech Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $145.1 Mil mean?
Genscript Biotech (GNNSF) has a Total Receivables of $145.1 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Genscript Biotech and its competitors.
Is Genscript Biotech's Total Receivables too high?
Genscript Biotech's current Total Receivables is $145.1 Mil. Overall, Genscript Biotech has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Total Receivables compare to VRTX and REGN?
Genscript Biotech's Total Receivables of $145.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Genscript Biotech and its competitors. Genscript Biotech's current Total Receivables is $145.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.50, compared to a current price of $1.60 — trading 36% below its estimated fair value. The current Total Receivables is $145.1 Mil. Genscript Biotech's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current Total Receivables is $145.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genscript Biotech (GNNSF) Overvalued in 2026?

Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued. The current stock price of $1.60 is trading 36% below its estimated GF Value™ of $2.50. GuruFocus considers Genscript Biotech to be Significantly Undervalued.

Key valuation signals for GNNSF:

  • Total Receivables: $145.1 Mil
  • GF Value™: $2.50 vs. price of $1.60 (36% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genscript Biotech Business Description

Other Exchanges 01548:Hong KongG51:Germany
Address 860 Centennial Avenue, Piscataway, NJ, USA, 08854
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
66GF Score

Get the complete analysis for GNNSF

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.60
Price
$2.50
GF Value